Clinical Trial Update: Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating zoledronic acid (Zometa) retention and effects in patients with multiple myeloma and breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Multiple Myeloma

Drugs mentioned

• Zometa (Zoledronic acid)

Snippet

Sponsor: Vejle Hospital | Conditions: Multiple Myeloma, Breast Cancer | Phase 2 | Status: COMPLETED